A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00111631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00111631
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 218 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2005 (Type not available)
- Primary completion
- Oct 2006 (Actual)
- Completion
- Oct 2006 (Actual)
- Last update posted
- Nov 2, 2016
2005 – 2006
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Concord | California | 94520 | — |
| Not listed | Salinas | California | 93901 | — |
| Not listed | San Diego | California | 92161 | — |
| Not listed | Boulder | Colorado | 80304 | — |
| Not listed | Newark | Delaware | 19713 | — |
| Not listed | Wilmington | Delaware | 19085 | — |
| Not listed | Clearwater | Florida | 33765 | — |
| Not listed | Miami | Florida | 33156 | — |
| Not listed | Chicago | Illinois | 60607 | — |
| Not listed | Detroit | Michigan | 48202-2689 | — |
| Not listed | Buffalo | New York | 14209 | — |
| Not listed | Rochester | New York | 14609 | — |
| Not listed | Durham | North Carolina | 27713 | — |
| Not listed | Mogadore | Ohio | 44260 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Connellsville | Pennsylvania | 15425 | — |
| Not listed | Warminster | Pennsylvania | 18974 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Midland | Texas | 79707 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2016 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00111631 live on ClinicalTrials.gov.